Guaraldi Giovanni, Murri Rita, Orlando Gabriella, Orlandi Emanuele, Sterrantino Gaetana, Borderi Marco, Grosso Carmela, Cattelan Anna Maria, Nardini Giulia, Beghetto Barbara, Antinori Andrea, Esposito Roberto, Wu Albert W
Department of Medical and Surgery Specialities, infectious Diseases Clinic, University of Modena and Reggio Emilia School of Medicine, Italy.
HIV Clin Trials. 2003 Mar-Apr;4(2):99-106. doi: 10.1310/W1QF-C9X9-9PFT-88JK.
To evaluate the association between adherence to drugs and morphologic alterations (MOA) in a cohort of HIV-infected patients on HAART.
This was a cross-sectional multicenter cohort study in eight tertiary Clinical Centers of Northern and Central Italy. Consecutive outpatients taking HAART were enrolled from August 2000 to March 2001. They completed a self-administered questionnaire for the evaluation of signs of MOA and the self-reported adherence to drugs. Main outcome measures were MOA according to the Multicenter AIDS Cohort Study (MACS) definition and adherence to drugs.
One hundred seventy-five persons were enrolled into the study. Median CD4 cell count was 522 (interquartile range [IQR] 306-720); 35% of people had undetectable HIV RNA. Patients had been taking HAART for a median of 53 months (IQR 33-62). Among enrolled patients, 83 (47%) had a diagnosis of self-reported MOA; 57 of them reported body changes of more than 12 months duration. Forty persons (23%) self-reported nonadherence in the previous week. Mean time on HAART was 48.7 months (SD = 19.7) for people with MOA and 42.1 months (SD = 21.8) for those without MOA (p =.043). The odds of adherence for people with MOA was 2.36 times (95% CI 1.11-5.00) higher than for people without MOA. On multivariate analysis, being older and female, having an undetectable HIV RNA, longer duration on HAART, and self-reported adherence were independently associated with the presence of MOA. In people with MOA, adherence seems to decrease over time.
Longer time on HAART and self-reported adherence were correlated to MOA. MOA was also associated with older age and female gender.
评估接受高效抗逆转录病毒治疗(HAART)的HIV感染患者队列中药物依从性与形态学改变(MOA)之间的关联。
这是一项在意大利北部和中部的八个三级临床中心进行的横断面多中心队列研究。2000年8月至2001年3月连续纳入接受HAART的门诊患者。他们完成了一份自我管理的问卷,用于评估MOA体征和自我报告的药物依从性。主要结局指标是根据多中心艾滋病队列研究(MACS)定义的MOA和药物依从性。
175人纳入研究。CD4细胞计数中位数为522(四分位间距[IQR]306 - 720);35%的人HIV RNA检测不到。患者接受HAART的时间中位数为53个月(IQR 33 - 62)。在纳入的患者中,83人(47%)自我报告有MOA诊断;其中57人报告身体变化持续超过12个月。40人(23%)自我报告在前一周未坚持服药。有MOA的人接受HAART的平均时间为48.7个月(标准差 = 19.7),无MOA的人为42.1个月(标准差 = 21.8)(p = 0.043)。有MOA的人坚持服药的几率比无MOA的人高2.36倍(95%置信区间1.11 - 5.00)。多因素分析显示,年龄较大、女性、HIV RNA检测不到、接受HAART时间较长以及自我报告的依从性与MOA的存在独立相关。在有MOA的人中,依从性似乎随时间下降。
接受HAART的时间较长和自我报告的依从性与MOA相关。MOA也与年龄较大和女性性别有关。